Tango Therapeutics, Inc. Income Statement

Income Statement Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Revenue & cost
Revenue 7.66M37.04M24.86M36.53M42.07M
Gross Profit 7.66M37.04M24.86M36.53M42.07M
Operating items
Research & Development 49.99M77.64M105.91M115.20M143.92M
Selling, General & Administrative 9.87M17.60M30.02M35.50M43.75M
Operating Expenses 59.86M95.23M135.93M150.70M187.66M
Operating Income -52.20M-58.19M-111.07M-114.17M-145.59M
EBIT -52.20M-58.19M-111.07M-114.17M-145.59M
Non-operating items
Non Operating Investment Income 0.01M-0.78M-2.94M3.89M0.15M
Other Non Operating Income 0.12M-0.25M1.49M5.94M7.61M
Non Operating Income 0.23M-0.25M2.95M12.56M15.50M
Net income details
EBT -51.97M-57.94M-108.12M-101.61M-130.09M
Tax Provisions 0.30M0.10M0.13M0.21M
Profit After Tax -51.97M-58.23M-108.18M-101.74M-130.30M
Income from Continuing Operations -51.97M-58.24M-108.22M-101.74M-130.30M
Consolidated Net Income -51.97M-58.24M-108.22M-101.74M-130.30M
Income towards Parent Company -51.97M-58.24M-108.22M-101.74M-130.30M
Net Income towards Common Stockholders -51.97M-58.24M-108.22M-101.74M-130.30M
Additional items
EPS (Basic) -0.00M-0.00M-0.00M-0.00M-0.00M
EPS (Weighted Average and Diluted) -0.00M-0.00M-0.00M-0.00M
Shares Outstanding (Weighted Average) 21.38M87.55M88.18M101.99M107.42M
Shares Outstanding (Diluted Average) 62.11M87.82M94.57M109.23M
EBITDA -51.97M-59.02M-111.12M-97.85M-130.15M